Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Biokinetics of [11C]Butanol in Healthy Volunteers
NCT04050800Phase 1Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carbon-11 butanol in neurodegenerative disease, sponsored by Weill Cornell Medicine. Primary endpoint: Effective Dose at 2 hours. Started Sep 2020; status: completed.
02
Drugs
carbon-11 butanol
03
Conditions
neurodegenerative disease
Beyond the preview
Go deeper on NCT04050800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04050800.